Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Rozerem To Launch In September Following FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Ramelteon clears FDA for "treatment of insomnia characterized by difficulty with sleep onset." Takeda is positioning Rozerem as the only prescription insomnia agent that does not carry controlled substance scheduling.

You may also be interested in...



Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share

Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.

Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share

Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.

Rozerem DTC Ads Highlight Low Abuse Potential Of Sleep Aid

Takeda launches Rozerem TV spots promoting sweet dreams with a humorous approach.

Related Content

Topics

UsernamePublicRestriction

Register

PS062619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel